HIV antiviral therapies

HIV antiviral therapies - Cell 284 smaller pieces of DNA...

Info iconThis preview shows pages 1–2. Sign up to view the full content.

View Full Document Right Arrow Icon
Cell 284 smaller pieces of DNA via recombination, or as modula- opportunistic infections and malignancies in male ho- mosexuals heralded the onset of the AIDS epidemic. The tors of gene expression through methylation of cis -act- ing transcriptional regulatory elements. Like some other subsequent identification of human immunodeficiency virus as the etiologic agent of AIDS led quickly to a infamous mucosal pathogens ( H. influenzae and Neisse- ria spp ), H. pylori uses slipped-strand mispairing to spur search for agents capable of inhibiting viral replication and restoring immune function. Since the first report its adaptive evolution within its host niche: the resulting frame-shift mutations act as switches to turn production of successful pharmacologic impact on HIV-1 disease progression in 1987, fifteen drugs belonging to three of proteins on or off. There is extensive discussion of how variation in gene content in the organism’s cag separate classes (nucleoside reverse transcriptase inhibi- tors [NRTI’s], non-nucleoside RT inhibitors [NNRTI’s], pathogenicity island (and the PAI’s type IV secretion system) are intimately linked to host responses. and protease inhibitors [PI’s]) have been approved for treatment of HIV-1 infection by the US Food and Drug The editors note in their preface that they wanted to create a book that “would summarize and review Administration, and over a dozen more are currently in development. The use of these agents has dramatically the accumulated knowledge on this important human pathogen.” They have succeeded. In 2004, exactly changed the clinical course of HIV-1 infection for those fortunate enough to have access (Palella et al., N. Engl. twenty years will have elapsed since the “big gulp.” The chances of making major advances in our understanding J. Med. 338 , 853–860, 1998). At the same time, this rapidly evolving field and the need to keep abreast of the biology of this microorganism and the determinants of its host relationships could not be brighter. DNA mi- new developments represents a growing challenge to croarrays containing more than 98% of the known ORFs clinicians and researcher alike. of the two sequenced strains are now available for whole Antiretroviral Therapy summarizes much of the prog- genome genotyping of clinical isolates (Salama et al., ress that has been made in the development of antiret- Proc. Natl. Acad. Sci. USA 97 , 14668–14673, 2000). Un- roviral therapeutic agents. Edited by Erik De Clercq, who dertaking a comprehensive screen for the presence or also coauthored several of the chapters, this book offers absence of bacterial genes in strains taken from defined a broad overview of each of the different classes of patient populations, or from individuals over the course drugs currently available for inhibition of HIV and reviews of their infection, provides an opportunity to build a progress toward the development of novel classes of knowledge base for correlating microbial and host phe-
Background image of page 1

Info iconThis preview has intentionally blurred sections. Sign up to view the full version.

View Full DocumentRight Arrow Icon
Image of page 2
This is the end of the preview. Sign up to access the rest of the document.

Page1 / 2

HIV antiviral therapies - Cell 284 smaller pieces of DNA...

This preview shows document pages 1 - 2. Sign up to view the full document.

View Full Document Right Arrow Icon
Ask a homework question - tutors are online